Pharmacokinetic considerations in selecting optimal antibiotic therapy for Mycoplasma pneumoniae encephalitis
- 41 Downloads
Effective antimicrobial therapy depends on several factors including degree of activity against the pathogen, antibiotic resistance, and when relevant, optimal tissue penetration factors. Central nervous system (CNS) infections illustrate these points well. The pharmacokinetic (PK) parameters important in antibiotic blood cerebrospinal fluid barrier (BCB) penetration that is important in meningitis are different and do not predict blood brain barrier (BBB) penetration. Recently, we had a case of Mycoplasma pneumoniae encephalitis (MPE) which prompted a review of the antibiotic PK determinants of BBB penetration which differ markedly from those of BCB penetration important in encephalitis. Using MPE as an illustrative example, this article reviews host and drug factors of therapeutic importance in optimally treating MPE.
KeywordsCNS manifestations of Mycoplasma pneumoniae Blood brain barrier (BBB) Antibiotic lipid solubility Tissue penetration of hydrophilic and hydrophilic antibiotics Antibiotic penetration across brain barrier (BPB)
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Cunha CB, Cunha BA (eds) (2017) Antibiotic essentials, 15th edn. Jay Pee Medical Publishers, New DelhiGoogle Scholar
- 2.Ristuccia A, Cunha BA (Eds) (1984) Antimicrobial Therapy Raven Press NYGoogle Scholar
- 3.Grayson ML (Ed) Kucers (2010) The use of antibiotics (6th Ed) Arnold Publishers LondonGoogle Scholar
- 5.Brodie BB, Kurz H, Schanker LS (1960) The importance of dissociation constant and lipid solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 130:20–25Google Scholar
- 6.Davson H, Smith H (1957) Discussion on the penetration of drugs into the cerebrospinal fluid. Proc R Soc Med 50:963–967Google Scholar
- 8.Wood W, Kipnis G (1953) The concentrations of tetracycline, chlortetracycline and oxytetracycline in the cerebrospinal fluid after intravenous injection. Antibiot Annu 4:98–101Google Scholar
- 9.Thrupp L, Leedom J, Tyler D, Wehrle P, Portnoy B, Mathies AW (1965) Ampicillin levels in the cerebrospinal fluid during the treatment of bacterial meningitis. Antimicrob Agents Chemother 5:206–213Google Scholar
- 16.Dinkel K, Ogle WO, Sapolsky RM (2002) Glucocorticooids and central nervous system inflammation. J Neuro-Oncol 8:513–528Google Scholar
- 21.Kumar R, Basu A, Sinha S, Das M, Tripath P, Jain A et al (2016) Role of oral minocycline in acute encephalitis syndrome in India – a randomized controlled trial. BMC Infect Dis 16:1385–1386Google Scholar